IL1B and atherosclerosis: PCA supplementation curtails IL-1β expression and NF-κB activation in lesions, inhibits the macrophage expression of IL-1b/IL-1β mRNA and protein, and initiates NF-κB activation through the upregulation of MERTK and MAPK 3/1, thereby lessening atherosclerosis severity [55].